Top of the morning to you, and a fine one it is. Despite gloomy skies hovering over the Pharmalot campus, our spirits remain upbeat and a hopeful outlook is unwavering. After all, as the Morning Mayor used to chant: Every brand new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will fire up the coffee kettle and prepare for yet another busy day. On that note, here are a few tidbits to inform you on your journey. Hope all goes well and, of course, do keep in touch. We enjoy hearing from you …

House Speaker Nancy Pelosi’s plan to lower drug costs is dramatically more aggressive than expected, STAT says. The plan is sure to please House progressives who have agitated for bold policy on drug prices but, as drafted, has almost no chance of winning conservative support. The plan allows the federal government to negotiate the price of 250 medicines and forces drug makers to offer those prices commercially, and would also dramatically alter the way Medicare divides responsibility for costs between drug makers, insurers, and taxpayers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy